Skip to content

ComPro Pharma

Active
Private limited companyfounded 2020active for 6 yearsRue d'Ogné 36, 4140 Sprimont, BelgiumKBO/BCE: BE 0746.429.351
Summary

ComPro Pharma has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €9,170 and a net result of €54,298. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 20% of 613 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Overview

Activity
Research and development on biotechnology
NACE 72101
1 site
Size
€76,879total assets 2025
Equity
€9,170
Profit
€54,298
Turnover not published (micro format)
Financial health
88 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
2025 accounts 64 days early1 deed in the Belgian Official Gazette
Why 88raises riskEquity €9,170 (11.9% of total assets)lowers riskSector: Scientific research and development (NACE 72)Liquidity: current ratio 0.69, cash €29,894Figures for financial year 2025 (filed 28-05-2026)Show the evidence

Checked score

Score 2025
88 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 48% of its sector peers (NACE 72, micro)
Financial strength · tick = 2024
Strong
Solvency 37+1
equity 11.9% of total assets
Liquidity 50-1
short-term debt 88.1% · cash 38.9%
Profitability 100=
return on assets 70.6%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.2%● unchanged vs 12-2024 02-2025: 0.2%● unchanged vs 01-2025 03-2025: 0.2%● unchanged vs 02-2025 04-2025: 0.2%● unchanged vs 03-2025 05-2025: 0.2%● unchanged vs 04-2025 06-2025: 0.1%▼ -0.1 percentage points vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025lowest value 02-2026: 0.1%● unchanged vs 01-2026lowest value 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.2%▲ +0.1 percentage points vs 05-2026 07-2026: 0.2%● unchanged vs 06-2026highest value 08-2026: 0.2%● unchanged vs 07-2026highest value 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026
Credit of up to €500 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.69, compared with 0.94 in 2024, below 1; short-term debt: 88.1% and cash: 38.9% of total assets), and 88.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 25% on solvency, 25% on liquidity, 90% on profitability and 53% on growth.

The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Seven signals.
lowers riskraises riskneutral
lowers risk · Sector: Scientific research and development (NACE 72)
KBO
lowers risk · Liquidity: current ratio 0.69, cash €29,894
NBB · annual accounts
raises risk · Equity €9,170 (11.9% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed 28-05-2026)
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 20% of 613 sector peers (2025).
NBB · sector comparison
Position among 613 sector peers
Solvency
better than 20%
← weakest strongest →
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
202122232425
2020 to 2025 · latest year €9,170
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-05-2026, 64 days ahead of the deadline.
NBB · 6 filings
Deviation from the deadline
2025
64 days early
2024
41 days early
2023
5 days early
2022
49 days early
2021
3 days early
2020
on the day
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 27 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 20 June (4 of the last 5 filed years within 37 days of that day).
Companies Code · seven months
Where today falls in the filing period
27-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Annual accounts filedfinancial year 2024 · micro…
  3. Highest result from 2020 to 2025net €56,892 ▲1.6%

Financials · financial year 2025, micro format

Turnover
€160,650▲ 10.4%
2022 · €145,500
EBIT margin
44.7%▲ 5.7pp
2022 · 39.0%
Net result
€54,298▼ 4.6%
2024 · €56,892
Working capital
-€20,726▼ 404%
2024 · -€4,110
Trend over the years

2021 to 2025, 5 financial years 2020 to 2025, 6 financial years

The operating result falls in 2025; 2025 is 3% below 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€160,650 2023 Operating result€69,588 2025 Net result€54,298 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).

Every figure with its change against the financial year before
favourable unfavourable
Line202020212022202320242025
Turnover€96,000-€145,235▲ 51.3%€145,500▲ 0.2%€160,650▲ 10.4%
Operating result€45,146-€60,897▲ 34.9%€56,742▼ 6.8%€71,828▲ 26.6%€71,913▲ 0.1%€69,588▼ 3.2%
Net result€35,353within the sector's middle half-€47,616within the sector's middle half▲ 34.7%€44,002within the sector's middle half▼ 7.6%€56,010within the sector's middle half▲ 27.3%€56,892within the sector's middle half▲ 1.6%€54,298within the sector's middle half▼ 4.6%
EBIT margin47.0%-41.9%▼ 5.1pp39.0%▼ 2.9pp44.7%▲ 5.7pp
Equity€39,353within the sector's middle half-€86,969within the sector's middle half▲ 121%€130,971within the sector's middle half▲ 50.6%€6,980below the sector's middle half▼ 94.7%€8,872below the sector's middle half▲ 27.1%€9,170below the sector's middle half▲ 3.4%
Total assets€57,423below the sector's middle half-€117,610below the sector's middle half▲ 105%€163,971within the sector's middle half▲ 39.4%€93,347below the sector's middle half▼ 43.1%€82,033below the sector's middle half▼ 12.1%€76,879below the sector's middle half▼ 6.3%
Debt€18,070-€30,641▲ 69.6%€33,000▲ 7.7%€86,367▲ 162%€73,161▼ 15.3%€67,709▼ 7.5%
Working capital€39,353within the sector's middle half-€86,969within the sector's middle half▲ 121%€130,971within the sector's middle half▲ 50.6%€6,980below the sector's middle half▼ 94.7%-€4,110below the sector's middle half-€20,726below the sector's middle half▼ 404%
Solvency68.5%within the sector's middle half-73.9%within the sector's middle half▲ 5.4pp79.9%within the sector's middle half▲ 5.9pp7.5%below the sector's middle half▼ 72.4pp10.8%below the sector's middle half▲ 3.3pp11.9%below the sector's middle half▲ 1.1pp
Current ratio3.18within the sector's middle half-3.84within the sector's middle half▲ 0.664.97within the sector's middle half▲ 1.131.08below the sector's middle half▼ 3.890.94below the sector's middle half▼ 0.140.69below the sector's middle half▼ 0.25
Return on assets (ROA)61.6%above the sector's middle half-40.5%above the sector's middle half▼ 21.1pp26.8%above the sector's middle half▼ 13.7pp60.0%above the sector's middle half▲ 33.2pp69.4%above the sector's middle half▲ 9.4pp70.6%above the sector's middle half▲ 1.3pp
above within below the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €76,879
Fixed assets €29,896 ▲ 130%
Current assets €46,982 ▼ 32.0%
Equity and liabilities €76,879
Equity €9,170 ▲ 3.4%
Debt €67,709 ▼ 7.5%
Debt's share of the balance-sheet total falls from 89.2% to 88.1%. Equity is higher and debt is lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€76,836▲
2024 · €73,742
Cash flow
€61,546▲
2024 · €58,720
Debt to equity
7.38▼
2024 · 8.25
ROE
592.1%▼
2024 · 641.3%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€67,709▼
2024 · €73,161
Income taxes
€15,257▼
2024 · €15,691
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 6,713 companies that looked in July 2024 the way this one looks now, 1.8% went bankrupt within 24 months and 95.8% are still going.

  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit of 5% of the balance sheet or more
1.8% went bankrupt
2.2% stopped otherwise
95.8% still going

A further 0.2% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: 0.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 6,713 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 41 lines
Balance sheet Code20242025
Assets
Total assets20/58€82,033€76,879▼
Fixed assets21/28€12,982€29,896▲
Tangible fixed assets22/27€12,982€6,896▼
Furniture and vehicles24€12,982€6,896▼
Financial fixed assets28-€23,000
Current assets29/58€69,051€46,982▼
Amounts receivable within one year40/41€15,972€15,972=
Trade receivables40€15,972€15,972=
Other amounts receivable41€0€0=
Cash at bank and in hand54/58€50,853€29,894▼
Deferred charges and accrued income490/1€2,226€1,117▼
Equity and liabilities
Total equity and liabilities10/49€82,033€76,879▼
Equity10/15€8,872€9,170▲
Contributions10/11€4,000€4,000=
Profit (loss) carried forward14€4,872€5,170▲
Amounts payable17/49€73,161€67,709▼
Amounts payable within one year42/48€73,161€67,709▼
Financial debts43€3€816▲
Credit institutions430/8€3€816▲
Trade debts44€1,980€1,139▼
Suppliers440/4€1,980€1,139▼
Taxes, remuneration and social security45€16,178€11,754▼
Taxes450/3€16,178€11,754▼
Remuneration and social security454/9€0€0=
Other amounts payable47/48€55,000€54,000▼
Income statement Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1,829€7,248▲
Other operating charges640/8€1,370€959▼
Gross operating margin9900€75,112€77,795▲
Operating profit (loss)9901€71,913€69,588▼
Financial income75/76B€871€173▼
Recurring financial income75€871€173▼
Financial charges65/66B€202€206▲
Recurring financial charges65€202€206▲
Profit (loss) for the period before taxes9903€72,583€69,555▼
Income taxes67/77€15,691€15,257▼
Profit (loss) for the period9904€56,892€54,298▼
Profit (loss) for the period to be appropriated9905€56,892€54,298▼
Appropriation of the result
Profit (loss) to be appropriated9906€59,872€59,170▼
Profit (loss) brought forward from the previous period14P€2,980€4,872▲
Profit to be distributed694/7€55,000€54,000▼
Return on contributions (dividend)694€55,000€54,000▼

The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line202020212022202320242025Change
Turnover70€96,000€145,235€145,500€160,650---
Goods, raw materials, services and sundry goods60/61-€87,211€92,284€93,891---
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630----€1,829€7,248▲ 296%
Other operating charges640/8-€385€432€836€1,370€959▼ 30.0%
Gross operating margin9900€45,820€61,282€57,173€72,664€75,112€77,795▲ 3.6%
Operating profit (loss)9901€45,146€60,897€56,742€71,828€71,913€69,588▼ 3.2%
Financial income75/76B---€82€871€173▼ 80.2%
Recurring financial income75€13--€82€871€173▼ 80.2%
Financial charges65/66B-€123€192€198€202€206▲ 1.7%
Recurring financial charges65€32€123€192€198€202€206▲ 1.7%
Profit (loss) for the period before taxes9903€45,127€60,773€56,549€71,713€72,583€69,555▼ 4.2%
Income taxes67/77€9,774€13,158€12,548€15,703€15,691€15,257▼ 2.8%
Profit (loss) for the period9904€35,353€47,616€44,002€56,010€56,892€54,298▼ 4.6%
Profit (loss) for the period to be appropriated9905€35,353€47,616€44,002€56,010€56,892€54,298▼ 4.6%
Line202020212022202320242025Change
Assets
Total assets20/58€57,423€117,610€163,971€93,347€82,033€76,879▼ 6.3%
Fixed assets21/28----€12,982€29,896▲ 130%
Tangible fixed assets22/27----€12,982€6,896▼ 46.9%
Furniture and vehicles24----€12,982€6,896▼ 46.9%
Financial fixed assets28-----€23,000-
Current assets29/58€57,423€117,610€163,971€93,347€69,051€46,982▼ 32.0%
Amounts receivable within one year40/41€14,833€0€14,520€15,972€15,972€15,972=
Trade receivables40-€0€14,520€15,972€15,972€15,972=
Other amounts receivable41-€0€0€0€0€0-
Cash at bank and in hand54/58€42,590€117,610€149,451€77,293€50,853€29,894▼ 41.2%
Deferred charges and accrued income490/1---€82€2,226€1,117▼ 49.8%
Equity and liabilities
Total equity and liabilities10/49€57,423€117,610€163,971€93,347€82,033€76,879▼ 6.3%
Equity10/15€39,353€86,969€130,971€6,980€8,872€9,170▲ 3.4%
Contributions10/11-€4,000€4,000€4,000€4,000€4,000=
Profit (loss) carried forward14€35,353€82,969€126,971€2,980€4,872€5,170▲ 6.1%
Amounts payable17/49€18,070€30,641€33,000€86,367€73,161€67,709▼ 7.5%
Amounts payable within one year42/48€18,070€30,641€33,000€86,367€73,161€67,709▼ 7.5%
Financial debts43-€0€88€3€3€816▲ 273×
Credit institutions430/8-€0€88€3€3€816▲ 273×
Trade debts44€1,184€360€112€239€1,980€1,139▼ 42.5%
Suppliers440/4-€360€112€239€1,980€1,139▼ 42.5%
Taxes, remuneration and social security45-€30,281€32,800€26,125€16,178€11,754▼ 27.3%
Taxes450/3-€30,281€32,800€26,125€16,178€11,754▼ 27.3%
Remuneration and social security454/9-€0€0€0€0€0-
Other amounts payable47/48---€60,000€55,000€54,000▼ 1.8%
Line202020212022202320242025Change
Profit (loss) for the period9904€35,353€47,616€44,002€56,010€56,892€54,298▼ 4.6%
+ Depreciation and write-downs630----€1,829€7,248▲ 296%
Operating cash flow (approximation)€35,353€47,616€44,002€56,010€58,720€61,546▲ 4.8%
Investment in fixed assets (approximation)------€24,162-
Change in cash-€75,019€31,841-€72,158-€26,440-€20,959▲ 20.7%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (6)
Financial year Type Filed Reference
31-12-2025 micro format 28-05-2026 2026-00124156
31-12-2024 micro format 20-06-2025 2025-00160851
31-12-2023 micro format 26-07-2024 2024-00296986
31-12-2022 micro format 12-06-2023 2023-00119149
31-12-2021 micro format 28-07-2022 2022-20259344
31-12-2020 micro format 31-07-2021 2021-45600439

Similar companies · same sector, comparable size

Of the 761 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 483. 124 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
No directors read yet: 0 of 1 Gazette act processed. See the directors and other office holders in the KBO →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

History

ComPro Pharma was incorporated on 21 April 2020 as a private limited company.1 Turnover grew from €96,000 in 2020 to €160,650 in 2023.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2020 and 2023

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
28-05
NBB filing Annual accounts filed
financial year 2025 · micro format
2025
20-06
NBB filing Annual accounts filed
financial year 2024 · micro format
2024
31-12
Financial Highest result from 2020 to 2025net €56,892 ▲1.6%
Operating result €71,913, net result €56,892, both a record.
26-07
NBB filing Annual accounts filed
financial year 2023 · micro format
2023
12-06
NBB filing Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial Equity above €100,000equity €130,971 ▲50.6%
A profit in every financial year since 2020 builds equity to €130,971.
28-07
NBB filing Annual accounts filed
financial year 2021 · micro format
2021
31-07
NBB filing Annual accounts filed
financial year 2020 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts

We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPrivate limited company
Founded21-04-2020
Financial year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
70200Business and other management consultancy
E-invoicing
Reachable via Peppol
Peppol ID 0208:0746429351
Also 9925:BE0746429351
Registered 07-11-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 27 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Legal Entity Identifier

6994003X0GTZ6YW7VK06
live in the LEI register

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Sprimont · 1 establishment unit since 2020
registered office establishment The establishment unit on the map
Ground area
3,080 m²
Building footprint
131 m²
Building volume
860 m³
Parcel 62100L0065/00G000, Wallonia · tallest building 8.4 m. Linked by address, not a title deed.
2 companies at this address See who is registered here
1 establishment unit
ComPro Pharma
Rue d'Ogné 36, 4140 SprimontResearch and development on biotechnology
since 2020unit no. 2.302.191.070
1 parcel
Wallonia 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
62100L0065/00G000 Wallonia 3,080 m² 1 · 131 m² 8.4 m · 2
How the parcels are linked
Good to know
The parcel matches the address exactly.